keyword
Keywords Neoadjuvant chemotherapy in lo...

Neoadjuvant chemotherapy in local advanced rectal cancer

https://read.qxmd.com/read/38309748/study-protocol-of-short-course-radiotherapy-combined-with-capox-and-pd-1-inhibitor-for-locally-advanced-colon-cancer-a-randomised-prospective-multicentre-phase-ii-trial-torch-c
#21
JOURNAL ARTICLE
Hui Zhang, Yaqi Li, Fan Xia, Yiqun Sun, Lijun Shen, Juefeng Wan, Yajie Chen, Yaqi Wang, Menglong Zhou, Ruiyan Wu, Shujuan Zhou, Yan Wang, Fangqi Liu, Sanjun Cai, Zhen Zhang
INTRODUCTION: The preliminary result of the TORCH trial has shown a promising complete response (CR) for managing locally advanced rectal cancer with neoadjuvant short-course radiotherapy (SCRT) combined with chemotherapy and PD-1 inhibitor. For locally advanced colon cancer (LACC) with bulky nodal disease and/or clinically T4, neoadjuvant chemotherapy followed by colectomy with en bloc removal of regional lymph nodes is the suggested treatment. However, the CR rate is less than 5%. TORCH-C will aim to investigate neoadjuvant SCRT combined with chemotherapy and PD-1 inhibitor in LACC...
February 2, 2024: BMJ Open
https://read.qxmd.com/read/38303278/-analysis-of-nuclear-%C3%AE-catenin-before-starting-treatment-could-potentially-predict-the-therapeutic-response-to-neoadjuvant-chemoradiotherapy-for-locally-advanced-rectal-cancer
#22
JOURNAL ARTICLE
Shoji Miyako, Takeru Matsuda, Takashi Kato, Masaki Shimizu, Ryuichiro Sawada, Hitoshi Harada, Naoki Urakawa, Hironobu Goto, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Taro Oshikiri, Yoshihiro Kakeji
Although a therapeutic response to neoadjuvant chemoradiotherapy(NACRT)is important to improve oncological outcomes after surgery in patients with locally advanced rectal cancer, there is no reliable predictor for this. The Wnt/β-catenin signal is known to be crucial for the tumorigenesis of colorectal cancer. This study aimed to investigate the association between Wnt/β-catenin signal activation and the response to NACRT in patients with locally advanced rectal cancer. We analyzed the expression of nuclear and membranous β-catenin in biopsy samples obtained from 60 patients who underwent curative surgery following NACRT...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38303199/-short-term-outcomes-of-neoadjuvant-chemoradiotherapy-for-locally-advanced-rectal-cancer
#23
JOURNAL ARTICLE
Yuki Sakamoto, Hidetaka Kurebayashi, Satoko Sakamoto, Takayuki Matsunaka, Nobuhiro Maegawa, Michiaki Shimada, Noriyuki Tagai, Katsuji Sawai, Mitsuhiro Morikawa, Kenji Koneri, Masato Tamaki, Makoto Murakami, Yasuo Hirono, Takanori Goi
In recent years, an increasing number of reports have demonstrated the usefulness of neoadjuvant chemoradiotherapy (NACRT). In our department, we consider cT3-4 and/or cN-positive locally advanced rectal cancer as an indication for NACRT. We have retrospectively evaluated the efficacy and safety of NACRT in 11 patients who underwent NACRT from November 2018 to July 2022. All patients were male, with a median age of 69 years, and cStage was Ⅱa: 1, Ⅱc: 1, Ⅲb: 5, Ⅲc: 3, and Ⅳa: 1...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38298433/a-pilot-study-on-the-safety-and-efficacy-of-neoadjuvant-chemo%C3%A2-adoptive-immunotherapy-for-locally-advanced-rectal-cancer
#24
JOURNAL ARTICLE
Yu Okazawa, Takashi Kamigaki, Kiichi Sugimoto, Takeshi Yamada, Yoichiro Yoshida, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Takuma Iwai, Akihisa Matsuda, Teppei Yamada, Suguru Hasegawa, Shigenori Goto, Rishu Takimoto, Kazuhiro Sakamoto
The safety and efficacy of combination therapy of immune cell therapy and chemotherapy [chemo-adoptive immunotherapy (CAIT)] for patients with stage IV or recurrent colorectal cancer have been reported. In the present study, the safety and efficacy of neoadjuvant CAIT were investigated for preoperative therapy of locally advanced rectal cancer. The study included patients with cT3/T4 or cN (+) rectal adenocarcinoma scheduled for curative surgery. Six patients who consented to participate in the current study were selected as subjects...
March 2024: Oncology Letters
https://read.qxmd.com/read/38289962/pharmacological-modulation-of-rb1-activity-mitigates-resistance-to-neoadjuvant-chemotherapy-in-locally-advanced-rectal-cancer
#25
JOURNAL ARTICLE
Zhaoliang Yu, Peng Deng, Yufeng Chen, Dezheng Lin, Shini Liu, Jinghan Hong, Peiyong Guan, Jianfeng Chen, Min-Er Zhong, Jinghong Chen, Xiaochuan Chen, Yichen Sun, Yali Wang, Peili Wang, Zerong Cai, Jason Yongsheng Chan, Yulin Huang, Rong Xiao, Yaoyu Guo, Xian Zeng, Wenyu Wang, Yifeng Zou, Qiang Yu, Ping Lan, Bin Tean Teh, Xiaojian Wu, Jing Tan
Resistance to neoadjuvant chemotherapy leads to poor prognosis of locally advanced rectal cancer (LARC), representing an unmet clinical need that demands further exploration of therapeutic strategies to improve clinical outcomes. Here, we identified a noncanonical role of RB1 for modulating chromatin activity that contributes to oxaliplatin resistance in colorectal cancer (CRC). We demonstrate that oxaliplatin induces RB1 phosphorylation, which is associated with the resistance to neoadjuvant oxaliplatin-based chemotherapy in LARC...
February 6, 2024: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/38273352/effect-of-adjuvant-chemotherapy-on-the-oncological-outcome-of-rectal-cancer-patients-with-pathological-complete-response
#26
JOURNAL ARTICLE
Jianguo Yang, Qican Deng, Yong Cheng, Zhongxue Fu, Xin Wu
BACKGROUND: Locally advanced rectal cancer is typically treated using a combination of neoadjuvant chemoradiotherapy and total mesorectal resection. While achieving pathological complete response following neoadjuvant chemoradiotherapy has been recognized as a positive prognostic factor in oncology, the necessity of adjuvant chemotherapy for locally advanced rectal cancer patients with pathological complete response after surgery remains uncertain. The objective of this meta-analysis was to examine the impact of adjuvant chemotherapy on the oncological outcomes of rectal cancer patients who attain pathological complete response after neoadjuvant chemoradiotherapy...
January 25, 2024: World Journal of Surgical Oncology
https://read.qxmd.com/read/38250676/neoadjuvant-s-1-and-oxaliplatin-plus-bevacizumab-therapy-for-high-risk-locally-advanced-rectal-cancer-a-prospective-multicenter-phase-ii-study
#27
JOURNAL ARTICLE
Takuya Miura, Hajime Morohashi, Yoshiyuki Sakamoto, Takuji Kagiya, Tatsuya Hasebe, Yoshihito Nakayama, Hiromasa Fujita, Kenichi Hakamada
AIM: We report the short/mid-term results of surgery for high-risk locally advanced rectal cancer (LARC) after neoadjuvant chemotherapy (NAC, four courses of S-1 + oxaliplatin+ bevacizumab) without radiotherapy with the primary aim of ypT0-2. METHODS: High-risk LARC was defined as cT4b, mesorectal fascia (MRF) ≤1 mm (MRF+), or lateral lymph node metastasis (cLLN+) on high-resolution MRI. The planned 32 cases from April 2018 to December 2021 were all included...
January 2024: Annals of Gastroenterological Surgery
https://read.qxmd.com/read/38248109/adoption-of-total-neoadjuvant-therapy-in-the-treatment-of-locally-advanced-rectal-cancer
#28
REVIEW
Madison L Conces, Amit Mahipal
Local and metastatic recurrence are primary concerns following the treatment of locally advanced rectal cancer (LARC). Chemoradiation (CRT) can reduce the local recurrence rates and has subsequently moved to the neoadjuvant setting from the adjuvant setting. Pathological complete response (pCR) rates have also been noted to be greater in patients treated with neoadjuvant CRT prior to surgery. The standard approach to treating LARC would often involve CRT followed by surgery and optional adjuvant chemotherapy and remained the treatment paradigm for almost two decades...
January 10, 2024: Current Oncology
https://read.qxmd.com/read/38241572/long-term-survival-in-a-patient-with-multiple-metastatic-gastric-cancer-treated-with-ptx-plus-emvolimab-and-disitamab-vedotin-case-report-and-treatment-experience-a-case-report
#29
JOURNAL ARTICLE
Yongjin Zhou, Meifeng Zhang, Li Dai, Zhiqiang Yan, Haibin Wang, Hongxin Yang, Xiangren Jin, Qian Wang
RATIONALE: Most Chinese patients with locally advanced gastric cancer at diagnosis have an overall 5-year survival rate of <50%. Surgical resection alone is not suitable for patients with locally advanced gastric cancer. Currently, comprehensive treatment is the focus of locally advanced gastric cancer. PATIENTS CONCERNS: The patient, a 56-year-old female, was admitted to the hospital because of "4 + months of double hydronephrosis found during a physical examination...
January 19, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38223404/treatment-options-for-neoadjuvant-strategies-of-esophageal-squamous-cell-carcinoma-review
#30
REVIEW
Hai Zeng, Fan Zhang, Yujiao Sun, Shuang Li, Weijia Zhang
Compared with postoperative adjuvant therapy, neoadjuvant therapy has more potential advantages, such as decreasing tumor stage, killing micrometastatic cells. Because of these advantages, neoadjuvant therapy is recommended for numerous types of tumor, such as breast, lung and rectal cancer. To determine the role of neoadjuvant therapy on overall survival and adverse for patients with resectable esophageal carcinoma. we summarized clinical studies on 7 types of neoadjuvant therapies in this review. Currently, patients with esophageal cancer (EC) in China mainly receive postoperative treatment with <30% of patients receiving neoadjuvant therapy...
January 2024: Molecular and Clinical Oncology
https://read.qxmd.com/read/38200410/anus-preservation-in-low-rectal-adenocarcinoma-based-on-mmr-msi-status-apram-a-study-protocol-for-a-randomised-controlled-open-label-multicentre-phase-iii-trial
#31
JOURNAL ARTICLE
Cheng-Yi Huang, Ming-Hua Bai, Jin-Wen Shen, Quan-Quan Sun, Yan-Ru Feng, Qian-Ping Chen, Wei Mao, Hai-Xing Ju, Ji Zhu
BACKGROUND: Anus preservation has been a challenge in the treatment of patients with low rectal adenocarcinoma (within 5 cm from the anal verge) because it is difficult to spare the anus with its functioning sphincter complex under the safe margin of tumour resection. Patients with dMMR/MSI-H can achieve a favourable complete response (CR) rate by using a single immune checkpoint inhibitor. For patients with pMMR/MSS/MSI-L, intensified neoadjuvant three-drug chemotherapy may be the preferred option for anal preservation...
January 10, 2024: BMC Cancer
https://read.qxmd.com/read/38194231/organ-preservation-and-survival-by-clinical-response-grade-in-patients-with-rectal-cancer-treated-with-total-neoadjuvant-therapy-a-secondary-analysis-of-the-opra-randomized-clinical-trial
#32
RANDOMIZED CONTROLLED TRIAL
Hannah M Thompson, Dana M Omer, Sabrina Lin, Jin K Kim, Jonathan B Yuval, Floris S Verheij, Li-Xuan Qin, Marc J Gollub, Abraham Jing-Ching Wu, Meghan Lee, Sujata Patil, Aram F Hezel, Jorge E Marcet, Peter A Cataldo, Blase N Polite, Daniel O Herzig, David Liska, Samuel Oommen, Charles M Friel, Charles A Ternent, Andrew L Coveler, Steven R Hunt, Julio Garcia-Aguilar
IMPORTANCE: Assessing clinical tumor response following completion of total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer is paramount to select patients for watch-and-wait treatment. OBJECTIVE: To assess organ preservation (OP) and oncologic outcomes according to clinical tumor response grade. DESIGN, SETTING, AND PARTICIPANTS: This was secondary analysis of the Organ Preservation in Patients with Rectal Adenocarcinoma trial, a phase 2, nonblinded, multicenter, randomized clinical trial...
January 2, 2024: JAMA Network Open
https://read.qxmd.com/read/38193472/-lipid-management-in-practice
#33
JOURNAL ARTICLE
Barbara Dehos, Stefan Bilz
Locally advanced rectal cancer has a high risk of local recurrence which can be reduced by multimodal therapy. Neoadjuvant radiotherapy or radiochemotherapy has been established. Nevertheless, this has not proved to improve overall survival. The benefit of adjuvant chemotherapy after neoadjuvant radiotherapy or radiochemotherapy remains unclear. Current studies are investigating total neoadjuvant therapy with different sequences of radiotherapy and chemotherapy followed by rectal resection. This procedure shows high pathologic complete remissions up to 28 % as well as an improvement in disease-free and metastasis-free survival...
December 2023: Praxis
https://read.qxmd.com/read/38157991/digitally-assessed-lymphocyte-infiltration-in-rectal-cancer-biopsies-is-associated-with-pathological-response-to-neoadjuvant-therapy
#34
JOURNAL ARTICLE
Dea Natalie Munch Jepsen, Henrik Høeg, Michael Bzorek, Adile Orhan, Jens Ole Eriksen, Ismail Gögenur, Björn Reiss, Anne-Marie Kanstrup Fiehn
A frequently used treatment strategy in locally advanced rectal cancer (RC) is neoadjuvant therapy followed by surgery. Patients treated with neoadjuvant therapy achieve varying pathological response, and currently, predicting the degree of response is challenging. This study examined the association between digitally assessed histopathological features in the diagnostic biopsies and pathological response to neoadjuvant therapy, aiming to find potential predictive biomarkers. 50 patients with RC treated with neoadjuvant chemotherapy and/or radiotherapy followed by surgery were included...
December 27, 2023: Human Pathology
https://read.qxmd.com/read/38143952/a-review-of-scheduling-strategies-for-radiotherapy-and-immune-checkpoint-inhibition-in-locally-advanced-rectal-cancer
#35
REVIEW
Lydia Melissourgou-Syka, Michael A Gillespie, Sean M O'Cathail, Owen J Sansom, Colin W Steele, Campbell S D Roxburgh
Colorectal cancer (CRC) is the third most common malignancy across the globe and, despite advances in treatment strategies, survival rates remain low. Rectal cancer (RC) accounts for most of these cases, and traditional management strategies for advanced disease include total neoadjuvant therapy (TNT) with chemoradiotherapy followed by curative surgery. Unfortunately, approximately 10-15% of patients have no response to treatment or have recurrence at a short interval following radiotherapy. The introduction of immunotherapy in the form of immune checkpoint blockade (ICB) in metastatic colorectal cancer has improved clinical outcomes, yet most patients with RC present with microsatellite stable disease, which lacks the immune-rich microenvironment where ICB is most effective...
November 2023: Journal of immunotherapy and precision oncology
https://read.qxmd.com/read/38141097/the-role-of-total-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-a-survey-of-specialists-attending-the-all-ireland-colorectal-cancer-conference-2022-including-lead-investigators-of-opra-prodige-23-and-rapido
#36
JOURNAL ARTICLE
Timothy O'Brien, Geke Hospers, Thierry Conroy, Heinz-Josef Lenz, Jesse Joshua Smith, Emmet Andrews, Brian O'Neill, Gregory Leonard
BACKGROUND: The treatment of locally advanced rectal cancer (LARC) has evolved following recent landmark trials of total neoadjuvant therapy (TNT)-the delivery of preoperative chemotherapy sequenced with radiation. AIM: To assess the preferences of colorectal surgery (CRS), radiation oncology (RO) and medical oncology (MO) specialists attending the All-Ireland Colorectal Cancer Conference (AICCC) 2022 regarding the neoadjuvant management of LARC. METHODS: A live electronic survey explored the preferred treatment approach and TNT regimen for early-, intermediate-, bad-, and advanced-risk categories of rectal cancer according to the European Society of Medical Oncology (ESMO) guidelines...
December 23, 2023: Irish Journal of Medical Science
https://read.qxmd.com/read/38124365/impact-of-consolidation-chemotherapy-in-poor-responders-to-neoadjuvant-radiation-therapy-magnetic-resonance-imaging-based-clinical-radiological-correlation-in-high-risk-rectal-cancers
#37
JOURNAL ARTICLE
Swapnil Patel, Suman Ankathi, Purvi Haria, Mufaddal Kazi, Ashwin L Desouza, Avanish Saklani
PURPOSE: The current study was conducted to examine the role of consolidation chemotherapy after neoadjuvant radiation therapy (NART) in decreasing the involvement of the mesorectal fascia (MRF) in high-risk locally advanced rectal cancers (LARCs). METHODS: In total, 46 patients who received consolidation chemotherapy after NART due to persistent MRF involvement were identified from a database. A team of 2 radiologists, blinded to the clinical data, studied sequential magnetic resonance imaging (MRI) scans to assess the tumor response and then predict a surgical plan...
December 21, 2023: Annals of Coloproctology
https://read.qxmd.com/read/38076602/unveiling-the-profound-advantages-of-total-neoadjuvant-therapy-in-rectal-cancer-a-trailblazing-exploration
#38
REVIEW
Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim, Donghyoun Lee, Chinock Cheong
The standard treatments for locally advanced rectal cancer typically involved neoadjuvant therapy with either short-course radiation or long-course chemoradiation, followed by radical surgery and adjuvant chemotherapy. While the advancement of surgical techniques and the adoption of multimodal therapy have greatly contributed to reducing local failure, there has been limited improvement in overall survival, primarily due to the stagnation in systemic failure. In response to this challenge, a new strategy known as total neoadjuvant therapy (TNT) has emerged, involving the administration of both full-dose chemotherapy and radiation before surgery...
December 2023: Annals of Surgical Treatment and Research
https://read.qxmd.com/read/38074695/comparing-real-world-outcomes-of-total-neoadjuvant-treatment-and-crt-at-a-tertiary-medical-center
#39
JOURNAL ARTICLE
Rim Turfa, Tala Alawabdeh, Ayman Naser, Yazan Alamro, Moath Albliwi, Sama Almasri, Abdullah Al Qazakzeh, Mohammad Abu Shattal, Ali Dabous, Rula Amarin
INTRODUCTION: For years, standard treatment for locally advanced rectal cancer (LARC) has included neoadjuvant chemoradiotherapy (CRT), followed by surgery and adjuvant chemotherapy. Although CRT has helped reduce local recurrence rates, it hasn't consistently improved overall survival. Recent trials have unveiled a different approach called total neoadjuvant treatment (TNT), involving pre-surgery radiotherapy followed by chemotherapy (CAPOX/FOLFOX). TNT shows promise with improved treatment response and lower distant metastasis rates without compromising local control...
2023: Frontiers in Oncology
https://read.qxmd.com/read/38074690/radiotherapy-in-the-preoperative-neoadjuvant-treatment-of-locally-advanced-rectal-cancer
#40
REVIEW
Zhen Yu, Yuying Hao, Yuhua Huang, Ling Ling, Xigang Hu, Simiao Qiao
Radiotherapy and chemotherapy are effective treatments for patients with locally advanced rectal cancer (LARC) and can significantly improve the likelihood of R0 resection. Radiotherapy can be used as a local treatment to reduce the size of the tumor, improve the success rate of surgery and reduce the residual cancer cells after surgery. Early chemotherapy can also downgrade the tumor and eliminate micrometastases throughout the body, reducing the risk of recurrence and metastasis. The advent of neoadjuvant concurrent radiotherapy (nCRT) and total neoadjuvant treatment (TNT) has brought substantial clinical benefits to patients with LARC...
2023: Frontiers in Oncology
keyword
keyword
61673
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.